Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary
- PMID: 14654523
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary
Abstract
Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials in this disease over the past several decades, and biology studies of tumor tissue have been an important study component. A meeting was held in Bethesda, Maryland on November 29-30, 2001, sponsored by the NIH Office of Rare Diseases, the Children's Oncology Group, and the National Cancer Institute-Cancer Therapy Evaluation Program with the general objectives: (a) to review the current state of knowledge regarding OS biology; (b) to identify, prioritize, and support the development of biology studies of potential clinical relevance in OS; and (c) to discuss the available tissue resources and the appropriate methods for analysis of OS samples for the conduct of biology studies. This report summarizes the information presented and discussed by the meeting participants.
Similar articles
-
Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.Expert Rev Anticancer Ther. 2007 Feb;7(2):169-81. doi: 10.1586/14737140.7.2.169. Expert Rev Anticancer Ther. 2007. PMID: 17288528 Review.
-
Osteogenic sarcoma (osteosarcoma) in the elderly: tumor delineation and predisposing conditions.Exp Gerontol. 2008 Dec;43(12):1039-43. doi: 10.1016/j.exger.2008.09.009. Epub 2008 Sep 25. Exp Gerontol. 2008. PMID: 18845233 Review.
-
Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome.J Clin Oncol. 2007 Feb 1;25(4):370-5. doi: 10.1200/JCO.2006.08.4558. J Clin Oncol. 2007. PMID: 17264332
-
Osteosarcoma treatment: state of the art.Cancer Metastasis Rev. 2009 Jun;28(1-2):247-63. doi: 10.1007/s10555-009-9186-7. Cancer Metastasis Rev. 2009. PMID: 19214708 Review.
-
Osteosarcoma: basic science and clinical implications.Orthop Clin North Am. 2006 Jan;37(1):1-7. doi: 10.1016/j.ocl.2005.06.004. Orthop Clin North Am. 2006. PMID: 16311106 Review.
Cited by
-
The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.Cancer Biol Ther. 2015;16(6):949-57. doi: 10.1080/15384047.2015.1040964. Epub 2015 Apr 28. Cancer Biol Ther. 2015. PMID: 25920748 Free PMC article.
-
Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.Cancers (Basel). 2021 May 2;13(9):2189. doi: 10.3390/cancers13092189. Cancers (Basel). 2021. PMID: 34063272 Free PMC article. Review.
-
mTOR: An attractive therapeutic target for osteosarcoma?Oncotarget. 2016 Aug 2;7(31):50805-50813. doi: 10.18632/oncotarget.9305. Oncotarget. 2016. PMID: 27177330 Free PMC article. Review.
-
Endocrine regulation and metabolic mechanisms of osteopontin in the development and progression of osteosarcoma, metastasis and prognosis.Front Endocrinol (Lausanne). 2023 Jan 13;13:1100063. doi: 10.3389/fendo.2022.1100063. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36714568 Free PMC article. Review.
-
Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats.Saudi J Biol Sci. 2022 Sep;29(9):103393. doi: 10.1016/j.sjbs.2022.103393. Epub 2022 Jul 25. Saudi J Biol Sci. 2022. PMID: 35957703 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous